{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-043232","form_type":"8-K","ticker":"VTGN","cik":"0001411685","company_name":"Vistagen Therapeutics, Inc.","filed_at":"2026-06-15T20:35:19+00:00","discovered_at":"2026-06-15T20:36:03.160769+00:00","generated_at":"2026-06-15T20:36:17.472438+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vistagen FY2026 net loss $69.7M; PALISADE-4 topline results expected June 2026","bullets":["Net loss of $69.7M for FY ended March 31, 2026, vs $51.4M prior year; R&D expense $55.0M.","Cash and marketable securities $45.4M; management expects runway into 2027.","Completed randomized portion of PALISADE-4 Phase 3 trial of fasedienol for social anxiety disorder; topline results expected in June 2026.","Received FDA 'Study May Proceed' letter for refisolone IND for menopausal hot flashes.","Appointed new CMO (Dr. Angel Angelov), CFO (Nick Tressler), and Chief Corporate Development Officer (Elissa Cote)."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-043232","json":"https://secwatch.observer/filing/0001628280-26-043232.json","markdown":"https://secwatch.observer/filing/0001628280-26-043232.md","text":"https://secwatch.observer/filing/0001628280-26-043232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/0001628280-26-043232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/vtgn-20260615.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T20:36:17.472438+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"17523acd00ed8aceda24b6bb503fd3edda14366e","claim":"Vistagen Therapeutics, Inc. reported fiscal year ended March 31, 2026 results: net income $69.7 million.","evidence_excerpt":"Net loss was $69.7 million for the fiscal year ended March 31, 2026, compared with $51.4 million for the fiscal year ended March 31, 2025.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1411685/000162828026043232/0001628280-26-043232-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fiscal year ended March 31, 2026"},{"label":"Net income","value":"$69.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}